Rimegepant, a small-molecule CGRP receptor antagonist, offers a flexible and well-tolerated migraine prevention option that uniquely bridges acute treatment and prophylaxis, with its role potentially expanding through combination therapies.
Dual-useRimegepant is uniquely approved for both acute migraine treatment and prevention, bridging two traditionally separate treatment approaches
What the researchers found
Rimegepant is positioned as a significant addition to migraine prophylaxis, distinguished by its dual use for both acute and preventive treatment — a capability unique among CGRP-targeting therapies. The review integrates evidence through 2025 and identifies several emerging directions:
- Situational prevention (using rimegepant around known migraine triggers)
- Potential combination with traditional preventives or anti-CGRP monoclonal antibodies
- Exploratory use in other CGRP-mediated headache disorders beyond migraine
The drug is described as well-tolerated with a favorable safety profile, though long-term persistence and safety monitoring remain important.
Why it matters
CGRP-targeting therapies have transformed migraine treatment, but most preventive options are injectable monoclonal antibodies requiring monthly or quarterly administration. Rimegepant offers an oral alternative that patients can use flexibly — both for acute attacks and prevention — potentially improving adherence and quality of life. Its ability to serve as a bridge between acute and preventive care is a paradigm shift in migraine management.
How the study worked
This is a narrative review with literature identified through PubMed/MEDLINE and Scopus searches (last search: November 19, 2025) using predefined search terms related to rimegepant and migraine. The review synthesizes pharmacological, clinical, safety, and regulatory evidence.
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis, so the evidence synthesis may not be comprehensive or unbiased. The abstract does not report specific efficacy numbers (e.g., reduction in monthly migraine days). Long-term safety data beyond the trial periods is limited. Reimbursement and cost remain significant barriers to clinical adoption. Real-world effectiveness may differ from clinical trial results.
How to read the evidence
This is a narrative review integrating clinical trial data, real-world evidence, and regulatory information. The underlying evidence includes randomized controlled trials, but this paper does not present original data or use systematic review methodology.
When this study was published
Published in 2026 with literature reviewed through November 2025, this is highly current and reflects the latest evidence on rimegepant's role in migraine management.
The bigger picture
The CGRP peptide pathway has become the most important therapeutic target in modern migraine medicine. While anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) were first to market, small-molecule CGRP receptor antagonists (gepants) like rimegepant offer oral convenience and scheduling flexibility. The concept of 'situational prevention' — taking rimegepant before known trigger exposures — represents a new treatment paradigm that leverages the drug's rapid onset and favorable safety profile.
Questions still open
- Can rimegepant be safely and effectively combined with anti-CGRP monoclonal antibodies for treatment-resistant migraine?
- How does rimegepant's long-term safety profile compare to traditional migraine preventives like topiramate or beta-blockers?
- Will the situational prevention concept prove effective in reducing overall migraine burden compared to daily prophylaxis?
Common questions
What is CGRP and why is it important in migraine?
How is rimegepant different from other CGRP-targeting migraine drugs?
Read the original research
Positioning rimegepant in migraine prophylaxis: updated evidence and emerging perspectives.
Expert review of neurotherapeutics, 1-9
Citation
Pellesi, Lanfranco; Scuteri, Damiana; Martelletti, Paolo. (2026). Positioning rimegepant in migraine prophylaxis: updated evidence and emerging perspectives.. Expert review of neurotherapeutics, 1-9. https://doi.org/10.1080/14737175.2026.2621879